nodes	percent_of_prediction	percent_of_DWPC	metapath
Salbutamol—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.0452	0.0879	CbGbCtD
Salbutamol—CYP3A4—Trimethadione—epilepsy syndrome	0.042	0.0817	CbGbCtD
Salbutamol—CYP3A4—Felbamate—epilepsy syndrome	0.042	0.0817	CbGbCtD
Salbutamol—CYP3A4—Fosphenytoin—epilepsy syndrome	0.0395	0.0768	CbGbCtD
Salbutamol—CYP3A4—Clonazepam—epilepsy syndrome	0.0357	0.0694	CbGbCtD
Salbutamol—CYP3A4—Clobazam—epilepsy syndrome	0.0342	0.0666	CbGbCtD
Salbutamol—CYP3A4—Rufinamide—epilepsy syndrome	0.0291	0.0566	CbGbCtD
Salbutamol—CYP3A4—Carbamazepine—epilepsy syndrome	0.0284	0.0552	CbGbCtD
Salbutamol—CYP3A4—Primidone—epilepsy syndrome	0.0265	0.0515	CbGbCtD
Salbutamol—CYP3A4—Phenytoin—epilepsy syndrome	0.0255	0.0495	CbGbCtD
Salbutamol—CYP3A4—Propofol—epilepsy syndrome	0.0237	0.0462	CbGbCtD
Salbutamol—CYP3A4—Acetazolamide—epilepsy syndrome	0.0227	0.0441	CbGbCtD
Salbutamol—CYP3A4—Phenobarbital—epilepsy syndrome	0.0227	0.0441	CbGbCtD
Salbutamol—CYP3A4—Midazolam—epilepsy syndrome	0.0224	0.0435	CbGbCtD
Salbutamol—CYP3A4—Diazepam—epilepsy syndrome	0.0215	0.0418	CbGbCtD
Salbutamol—CYP3A4—Zonisamide—epilepsy syndrome	0.021	0.0408	CbGbCtD
Salbutamol—CYP3A4—Valproic Acid—epilepsy syndrome	0.017	0.033	CbGbCtD
Salbutamol—CYP3A4—Topiramate—epilepsy syndrome	0.0153	0.0297	CbGbCtD
Salbutamol—Clenbuterol—NGF—epilepsy syndrome	0.00288	0.482	CrCbGaD
Salbutamol—Terbutaline—BCHE—epilepsy syndrome	0.00072	0.121	CrCbGaD
Salbutamol—Clenbuterol—TNF—epilepsy syndrome	0.000558	0.0935	CrCbGaD
Salbutamol—Levonordefrin—ADRA2A—epilepsy syndrome	0.00046	0.077	CrCbGaD
Salbutamol—Carteolol—CYP2D6—epilepsy syndrome	0.000367	0.0615	CrCbGaD
Salbutamol—Norepinephrine—ADRA2A—epilepsy syndrome	0.000273	0.0456	CrCbGaD
Salbutamol—Epinephrine—ADRA2A—epilepsy syndrome	0.000247	0.0414	CrCbGaD
Salbutamol—Epinephrine—TNF—epilepsy syndrome	0.000235	0.0393	CrCbGaD
Salbutamol—Nadolol—ABCB1—epilepsy syndrome	0.000234	0.0391	CrCbGaD
Salbutamol—Pruritus—Oxcarbazepine—epilepsy syndrome	8.07e-05	0.000206	CcSEcCtD
Salbutamol—Hypersensitivity—Carbamazepine—epilepsy syndrome	8.06e-05	0.000206	CcSEcCtD
Salbutamol—Headache—Vigabatrin—epilepsy syndrome	8.04e-05	0.000205	CcSEcCtD
Salbutamol—Hypertension—Pregabalin—epilepsy syndrome	8.03e-05	0.000205	CcSEcCtD
Salbutamol—Vomiting—Diazepam—epilepsy syndrome	8.03e-05	0.000205	CcSEcCtD
Salbutamol—Anorexia—Valproic Acid—epilepsy syndrome	8.01e-05	0.000205	CcSEcCtD
Salbutamol—Tremor—Gabapentin—epilepsy syndrome	8e-05	0.000204	CcSEcCtD
Salbutamol—Rash—Diazepam—epilepsy syndrome	7.97e-05	0.000204	CcSEcCtD
Salbutamol—Dermatitis—Diazepam—epilepsy syndrome	7.96e-05	0.000203	CcSEcCtD
Salbutamol—Myalgia—Pregabalin—epilepsy syndrome	7.92e-05	0.000202	CcSEcCtD
Salbutamol—Arthralgia—Pregabalin—epilepsy syndrome	7.92e-05	0.000202	CcSEcCtD
Salbutamol—Chest pain—Pregabalin—epilepsy syndrome	7.92e-05	0.000202	CcSEcCtD
Salbutamol—Ill-defined disorder—Gabapentin—epilepsy syndrome	7.92e-05	0.000202	CcSEcCtD
Salbutamol—Dizziness—Zonisamide—epilepsy syndrome	7.92e-05	0.000202	CcSEcCtD
Salbutamol—Headache—Diazepam—epilepsy syndrome	7.92e-05	0.000202	CcSEcCtD
Salbutamol—Anxiety—Pregabalin—epilepsy syndrome	7.9e-05	0.000202	CcSEcCtD
Salbutamol—Diarrhoea—Clonazepam—epilepsy syndrome	7.89e-05	0.000202	CcSEcCtD
Salbutamol—Hypotension—Valproic Acid—epilepsy syndrome	7.85e-05	0.000201	CcSEcCtD
Salbutamol—Asthenia—Carbamazepine—epilepsy syndrome	7.85e-05	0.000201	CcSEcCtD
Salbutamol—Agitation—Gabapentin—epilepsy syndrome	7.84e-05	0.0002	CcSEcCtD
Salbutamol—Diarrhoea—Phenytoin—epilepsy syndrome	7.84e-05	0.0002	CcSEcCtD
Salbutamol—Discomfort—Pregabalin—epilepsy syndrome	7.83e-05	0.0002	CcSEcCtD
Salbutamol—Nausea—Fosphenytoin—epilepsy syndrome	7.82e-05	0.0002	CcSEcCtD
Salbutamol—Diarrhoea—Oxcarbazepine—epilepsy syndrome	7.8e-05	0.000199	CcSEcCtD
Salbutamol—Angioedema—Gabapentin—epilepsy syndrome	7.8e-05	0.000199	CcSEcCtD
Salbutamol—Hypersensitivity—Lamotrigine—epilepsy syndrome	7.79e-05	0.000199	CcSEcCtD
Salbutamol—Vomiting—Felbamate—epilepsy syndrome	7.78e-05	0.000199	CcSEcCtD
Salbutamol—Dry mouth—Pregabalin—epilepsy syndrome	7.75e-05	0.000198	CcSEcCtD
Salbutamol—Pruritus—Carbamazepine—epilepsy syndrome	7.74e-05	0.000198	CcSEcCtD
Salbutamol—Rash—Felbamate—epilepsy syndrome	7.71e-05	0.000197	CcSEcCtD
Salbutamol—Dermatitis—Felbamate—epilepsy syndrome	7.7e-05	0.000197	CcSEcCtD
Salbutamol—Malaise—Gabapentin—epilepsy syndrome	7.7e-05	0.000197	CcSEcCtD
Salbutamol—Tinnitus—Topiramate—epilepsy syndrome	7.69e-05	0.000196	CcSEcCtD
Salbutamol—Vertigo—Gabapentin—epilepsy syndrome	7.67e-05	0.000196	CcSEcCtD
Salbutamol—Headache—Felbamate—epilepsy syndrome	7.66e-05	0.000196	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	7.65e-05	0.000196	CcSEcCtD
Salbutamol—Cardiac disorder—Topiramate—epilepsy syndrome	7.65e-05	0.000196	CcSEcCtD
Salbutamol—Flushing—Topiramate—epilepsy syndrome	7.65e-05	0.000196	CcSEcCtD
Salbutamol—Syncope—Gabapentin—epilepsy syndrome	7.65e-05	0.000196	CcSEcCtD
Salbutamol—Dizziness—Clonazepam—epilepsy syndrome	7.63e-05	0.000195	CcSEcCtD
Salbutamol—Nausea—Vigabatrin—epilepsy syndrome	7.62e-05	0.000195	CcSEcCtD
Salbutamol—Vomiting—Zonisamide—epilepsy syndrome	7.61e-05	0.000194	CcSEcCtD
Salbutamol—Insomnia—Valproic Acid—epilepsy syndrome	7.6e-05	0.000194	CcSEcCtD
Salbutamol—Oedema—Pregabalin—epilepsy syndrome	7.6e-05	0.000194	CcSEcCtD
Salbutamol—Anaphylactic shock—Pregabalin—epilepsy syndrome	7.6e-05	0.000194	CcSEcCtD
Salbutamol—Asthenia—Lamotrigine—epilepsy syndrome	7.59e-05	0.000194	CcSEcCtD
Salbutamol—Dizziness—Phenytoin—epilepsy syndrome	7.58e-05	0.000194	CcSEcCtD
Salbutamol—Rash—Zonisamide—epilepsy syndrome	7.55e-05	0.000193	CcSEcCtD
Salbutamol—Infection—Pregabalin—epilepsy syndrome	7.55e-05	0.000193	CcSEcCtD
Salbutamol—Paraesthesia—Valproic Acid—epilepsy syndrome	7.54e-05	0.000193	CcSEcCtD
Salbutamol—Palpitations—Gabapentin—epilepsy syndrome	7.54e-05	0.000193	CcSEcCtD
Salbutamol—Dermatitis—Zonisamide—epilepsy syndrome	7.54e-05	0.000193	CcSEcCtD
Salbutamol—Dizziness—Oxcarbazepine—epilepsy syndrome	7.54e-05	0.000193	CcSEcCtD
Salbutamol—Nausea—Diazepam—epilepsy syndrome	7.51e-05	0.000192	CcSEcCtD
Salbutamol—Loss of consciousness—Gabapentin—epilepsy syndrome	7.5e-05	0.000192	CcSEcCtD
Salbutamol—Headache—Zonisamide—epilepsy syndrome	7.5e-05	0.000192	CcSEcCtD
Salbutamol—Dyspnoea—Valproic Acid—epilepsy syndrome	7.49e-05	0.000191	CcSEcCtD
Salbutamol—Diarrhoea—Carbamazepine—epilepsy syndrome	7.49e-05	0.000191	CcSEcCtD
Salbutamol—Angiopathy—Topiramate—epilepsy syndrome	7.48e-05	0.000191	CcSEcCtD
Salbutamol—Pruritus—Lamotrigine—epilepsy syndrome	7.48e-05	0.000191	CcSEcCtD
Salbutamol—Shock—Pregabalin—epilepsy syndrome	7.47e-05	0.000191	CcSEcCtD
Salbutamol—Somnolence—Valproic Acid—epilepsy syndrome	7.47e-05	0.000191	CcSEcCtD
Salbutamol—Immune system disorder—Topiramate—epilepsy syndrome	7.45e-05	0.00019	CcSEcCtD
Salbutamol—Nervous system disorder—Pregabalin—epilepsy syndrome	7.45e-05	0.00019	CcSEcCtD
Salbutamol—Cough—Gabapentin—epilepsy syndrome	7.45e-05	0.00019	CcSEcCtD
Salbutamol—Mediastinal disorder—Topiramate—epilepsy syndrome	7.43e-05	0.00019	CcSEcCtD
Salbutamol—Tachycardia—Pregabalin—epilepsy syndrome	7.41e-05	0.000189	CcSEcCtD
Salbutamol—Chills—Topiramate—epilepsy syndrome	7.4e-05	0.000189	CcSEcCtD
Salbutamol—Dyspepsia—Valproic Acid—epilepsy syndrome	7.4e-05	0.000189	CcSEcCtD
Salbutamol—Skin disorder—Pregabalin—epilepsy syndrome	7.38e-05	0.000188	CcSEcCtD
Salbutamol—Hypertension—Gabapentin—epilepsy syndrome	7.37e-05	0.000188	CcSEcCtD
Salbutamol—Hyperhidrosis—Pregabalin—epilepsy syndrome	7.34e-05	0.000188	CcSEcCtD
Salbutamol—Vomiting—Clonazepam—epilepsy syndrome	7.34e-05	0.000187	CcSEcCtD
Salbutamol—Decreased appetite—Valproic Acid—epilepsy syndrome	7.3e-05	0.000187	CcSEcCtD
Salbutamol—Vomiting—Phenytoin—epilepsy syndrome	7.29e-05	0.000186	CcSEcCtD
Salbutamol—Rash—Clonazepam—epilepsy syndrome	7.27e-05	0.000186	CcSEcCtD
Salbutamol—Dermatitis—Clonazepam—epilepsy syndrome	7.27e-05	0.000186	CcSEcCtD
Salbutamol—Chest pain—Gabapentin—epilepsy syndrome	7.27e-05	0.000186	CcSEcCtD
Salbutamol—Arthralgia—Gabapentin—epilepsy syndrome	7.27e-05	0.000186	CcSEcCtD
Salbutamol—Myalgia—Gabapentin—epilepsy syndrome	7.27e-05	0.000186	CcSEcCtD
Salbutamol—Nausea—Felbamate—epilepsy syndrome	7.26e-05	0.000186	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	7.25e-05	0.000185	CcSEcCtD
Salbutamol—Vomiting—Oxcarbazepine—epilepsy syndrome	7.25e-05	0.000185	CcSEcCtD
Salbutamol—Fatigue—Valproic Acid—epilepsy syndrome	7.24e-05	0.000185	CcSEcCtD
Salbutamol—Anxiety—Gabapentin—epilepsy syndrome	7.24e-05	0.000185	CcSEcCtD
Salbutamol—Anorexia—Pregabalin—epilepsy syndrome	7.24e-05	0.000185	CcSEcCtD
Salbutamol—Dizziness—Carbamazepine—epilepsy syndrome	7.23e-05	0.000185	CcSEcCtD
Salbutamol—Diarrhoea—Lamotrigine—epilepsy syndrome	7.23e-05	0.000185	CcSEcCtD
Salbutamol—Headache—Clonazepam—epilepsy syndrome	7.23e-05	0.000185	CcSEcCtD
Salbutamol—Rash—Phenytoin—epilepsy syndrome	7.23e-05	0.000185	CcSEcCtD
Salbutamol—Mental disorder—Topiramate—epilepsy syndrome	7.23e-05	0.000185	CcSEcCtD
Salbutamol—Dermatitis—Phenytoin—epilepsy syndrome	7.22e-05	0.000184	CcSEcCtD
Salbutamol—Rash—Oxcarbazepine—epilepsy syndrome	7.19e-05	0.000184	CcSEcCtD
Salbutamol—Constipation—Valproic Acid—epilepsy syndrome	7.18e-05	0.000184	CcSEcCtD
Salbutamol—Pain—Valproic Acid—epilepsy syndrome	7.18e-05	0.000184	CcSEcCtD
Salbutamol—Dermatitis—Oxcarbazepine—epilepsy syndrome	7.18e-05	0.000183	CcSEcCtD
Salbutamol—Headache—Phenytoin—epilepsy syndrome	7.18e-05	0.000183	CcSEcCtD
Salbutamol—Malnutrition—Topiramate—epilepsy syndrome	7.18e-05	0.000183	CcSEcCtD
Salbutamol—Discomfort—Gabapentin—epilepsy syndrome	7.18e-05	0.000183	CcSEcCtD
Salbutamol—Headache—Oxcarbazepine—epilepsy syndrome	7.14e-05	0.000182	CcSEcCtD
Salbutamol—Nausea—Zonisamide—epilepsy syndrome	7.11e-05	0.000182	CcSEcCtD
Salbutamol—Dry mouth—Gabapentin—epilepsy syndrome	7.11e-05	0.000182	CcSEcCtD
Salbutamol—Hypotension—Pregabalin—epilepsy syndrome	7.1e-05	0.000181	CcSEcCtD
Salbutamol—Flatulence—Topiramate—epilepsy syndrome	7.07e-05	0.000181	CcSEcCtD
Salbutamol—Tension—Topiramate—epilepsy syndrome	7.05e-05	0.00018	CcSEcCtD
Salbutamol—Dysgeusia—Topiramate—epilepsy syndrome	7.03e-05	0.00018	CcSEcCtD
Salbutamol—Dizziness—Lamotrigine—epilepsy syndrome	6.99e-05	0.000179	CcSEcCtD
Salbutamol—Nervousness—Topiramate—epilepsy syndrome	6.97e-05	0.000178	CcSEcCtD
Salbutamol—Oedema—Gabapentin—epilepsy syndrome	6.96e-05	0.000178	CcSEcCtD
Salbutamol—Anaphylactic shock—Gabapentin—epilepsy syndrome	6.96e-05	0.000178	CcSEcCtD
Salbutamol—Vomiting—Carbamazepine—epilepsy syndrome	6.96e-05	0.000178	CcSEcCtD
Salbutamol—Back pain—Topiramate—epilepsy syndrome	6.94e-05	0.000177	CcSEcCtD
Salbutamol—Feeling abnormal—Valproic Acid—epilepsy syndrome	6.92e-05	0.000177	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	6.92e-05	0.000177	CcSEcCtD
Salbutamol—Infection—Gabapentin—epilepsy syndrome	6.92e-05	0.000177	CcSEcCtD
Salbutamol—Muscle spasms—Topiramate—epilepsy syndrome	6.9e-05	0.000176	CcSEcCtD
Salbutamol—Rash—Carbamazepine—epilepsy syndrome	6.9e-05	0.000176	CcSEcCtD
Salbutamol—Dermatitis—Carbamazepine—epilepsy syndrome	6.89e-05	0.000176	CcSEcCtD
Salbutamol—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	6.87e-05	0.000176	CcSEcCtD
Salbutamol—Insomnia—Pregabalin—epilepsy syndrome	6.87e-05	0.000175	CcSEcCtD
Salbutamol—Nausea—Clonazepam—epilepsy syndrome	6.85e-05	0.000175	CcSEcCtD
Salbutamol—Headache—Carbamazepine—epilepsy syndrome	6.85e-05	0.000175	CcSEcCtD
Salbutamol—Shock—Gabapentin—epilepsy syndrome	6.85e-05	0.000175	CcSEcCtD
Salbutamol—Nervous system disorder—Gabapentin—epilepsy syndrome	6.83e-05	0.000174	CcSEcCtD
Salbutamol—Paraesthesia—Pregabalin—epilepsy syndrome	6.82e-05	0.000174	CcSEcCtD
Salbutamol—Nausea—Phenytoin—epilepsy syndrome	6.81e-05	0.000174	CcSEcCtD
Salbutamol—Tachycardia—Gabapentin—epilepsy syndrome	6.8e-05	0.000174	CcSEcCtD
Salbutamol—Dyspnoea—Pregabalin—epilepsy syndrome	6.77e-05	0.000173	CcSEcCtD
Salbutamol—Nausea—Oxcarbazepine—epilepsy syndrome	6.77e-05	0.000173	CcSEcCtD
Salbutamol—Skin disorder—Gabapentin—epilepsy syndrome	6.77e-05	0.000173	CcSEcCtD
Salbutamol—Somnolence—Pregabalin—epilepsy syndrome	6.75e-05	0.000172	CcSEcCtD
Salbutamol—Hyperhidrosis—Gabapentin—epilepsy syndrome	6.73e-05	0.000172	CcSEcCtD
Salbutamol—Tremor—Topiramate—epilepsy syndrome	6.73e-05	0.000172	CcSEcCtD
Salbutamol—Vomiting—Lamotrigine—epilepsy syndrome	6.72e-05	0.000172	CcSEcCtD
Salbutamol—Urticaria—Valproic Acid—epilepsy syndrome	6.67e-05	0.000171	CcSEcCtD
Salbutamol—Rash—Lamotrigine—epilepsy syndrome	6.67e-05	0.00017	CcSEcCtD
Salbutamol—Ill-defined disorder—Topiramate—epilepsy syndrome	6.66e-05	0.00017	CcSEcCtD
Salbutamol—Dermatitis—Lamotrigine—epilepsy syndrome	6.66e-05	0.00017	CcSEcCtD
Salbutamol—Body temperature increased—Valproic Acid—epilepsy syndrome	6.64e-05	0.00017	CcSEcCtD
Salbutamol—Abdominal pain—Valproic Acid—epilepsy syndrome	6.64e-05	0.00017	CcSEcCtD
Salbutamol—Anorexia—Gabapentin—epilepsy syndrome	6.64e-05	0.00017	CcSEcCtD
Salbutamol—Headache—Lamotrigine—epilepsy syndrome	6.62e-05	0.000169	CcSEcCtD
Salbutamol—Decreased appetite—Pregabalin—epilepsy syndrome	6.6e-05	0.000169	CcSEcCtD
Salbutamol—Agitation—Topiramate—epilepsy syndrome	6.6e-05	0.000169	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	6.56e-05	0.000168	CcSEcCtD
Salbutamol—Fatigue—Pregabalin—epilepsy syndrome	6.55e-05	0.000167	CcSEcCtD
Salbutamol—Hypotension—Gabapentin—epilepsy syndrome	6.51e-05	0.000166	CcSEcCtD
Salbutamol—Nausea—Carbamazepine—epilepsy syndrome	6.5e-05	0.000166	CcSEcCtD
Salbutamol—Constipation—Pregabalin—epilepsy syndrome	6.5e-05	0.000166	CcSEcCtD
Salbutamol—Pain—Pregabalin—epilepsy syndrome	6.5e-05	0.000166	CcSEcCtD
Salbutamol—Malaise—Topiramate—epilepsy syndrome	6.47e-05	0.000165	CcSEcCtD
Salbutamol—Vertigo—Topiramate—epilepsy syndrome	6.45e-05	0.000165	CcSEcCtD
Salbutamol—Syncope—Topiramate—epilepsy syndrome	6.44e-05	0.000164	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	6.35e-05	0.000162	CcSEcCtD
Salbutamol—Palpitations—Topiramate—epilepsy syndrome	6.34e-05	0.000162	CcSEcCtD
Salbutamol—Loss of consciousness—Topiramate—epilepsy syndrome	6.31e-05	0.000161	CcSEcCtD
Salbutamol—Insomnia—Gabapentin—epilepsy syndrome	6.3e-05	0.000161	CcSEcCtD
Salbutamol—Nausea—Lamotrigine—epilepsy syndrome	6.28e-05	0.00016	CcSEcCtD
Salbutamol—Cough—Topiramate—epilepsy syndrome	6.27e-05	0.00016	CcSEcCtD
Salbutamol—Feeling abnormal—Pregabalin—epilepsy syndrome	6.26e-05	0.00016	CcSEcCtD
Salbutamol—Paraesthesia—Gabapentin—epilepsy syndrome	6.25e-05	0.00016	CcSEcCtD
Salbutamol—Gastrointestinal pain—Pregabalin—epilepsy syndrome	6.21e-05	0.000159	CcSEcCtD
Salbutamol—Dyspnoea—Gabapentin—epilepsy syndrome	6.21e-05	0.000159	CcSEcCtD
Salbutamol—Hypertension—Topiramate—epilepsy syndrome	6.2e-05	0.000158	CcSEcCtD
Salbutamol—Somnolence—Gabapentin—epilepsy syndrome	6.19e-05	0.000158	CcSEcCtD
Salbutamol—Hypersensitivity—Valproic Acid—epilepsy syndrome	6.19e-05	0.000158	CcSEcCtD
Salbutamol—Dyspepsia—Gabapentin—epilepsy syndrome	6.13e-05	0.000157	CcSEcCtD
Salbutamol—Chest pain—Topiramate—epilepsy syndrome	6.11e-05	0.000156	CcSEcCtD
Salbutamol—Arthralgia—Topiramate—epilepsy syndrome	6.11e-05	0.000156	CcSEcCtD
Salbutamol—Myalgia—Topiramate—epilepsy syndrome	6.11e-05	0.000156	CcSEcCtD
Salbutamol—Anxiety—Topiramate—epilepsy syndrome	6.09e-05	0.000156	CcSEcCtD
Salbutamol—Decreased appetite—Gabapentin—epilepsy syndrome	6.05e-05	0.000155	CcSEcCtD
Salbutamol—Discomfort—Topiramate—epilepsy syndrome	6.04e-05	0.000154	CcSEcCtD
Salbutamol—Urticaria—Pregabalin—epilepsy syndrome	6.03e-05	0.000154	CcSEcCtD
Salbutamol—Asthenia—Valproic Acid—epilepsy syndrome	6.03e-05	0.000154	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	6.01e-05	0.000154	CcSEcCtD
Salbutamol—Fatigue—Gabapentin—epilepsy syndrome	6e-05	0.000153	CcSEcCtD
Salbutamol—Abdominal pain—Pregabalin—epilepsy syndrome	6e-05	0.000153	CcSEcCtD
Salbutamol—Body temperature increased—Pregabalin—epilepsy syndrome	6e-05	0.000153	CcSEcCtD
Salbutamol—Dry mouth—Topiramate—epilepsy syndrome	5.98e-05	0.000153	CcSEcCtD
Salbutamol—Pain—Gabapentin—epilepsy syndrome	5.96e-05	0.000152	CcSEcCtD
Salbutamol—Constipation—Gabapentin—epilepsy syndrome	5.96e-05	0.000152	CcSEcCtD
Salbutamol—Pruritus—Valproic Acid—epilepsy syndrome	5.94e-05	0.000152	CcSEcCtD
Salbutamol—Oedema—Topiramate—epilepsy syndrome	5.86e-05	0.00015	CcSEcCtD
Salbutamol—Infection—Topiramate—epilepsy syndrome	5.82e-05	0.000149	CcSEcCtD
Salbutamol—Shock—Topiramate—epilepsy syndrome	5.76e-05	0.000147	CcSEcCtD
Salbutamol—Diarrhoea—Valproic Acid—epilepsy syndrome	5.75e-05	0.000147	CcSEcCtD
Salbutamol—Nervous system disorder—Topiramate—epilepsy syndrome	5.75e-05	0.000147	CcSEcCtD
Salbutamol—Feeling abnormal—Gabapentin—epilepsy syndrome	5.74e-05	0.000147	CcSEcCtD
Salbutamol—Tachycardia—Topiramate—epilepsy syndrome	5.72e-05	0.000146	CcSEcCtD
Salbutamol—Gastrointestinal pain—Gabapentin—epilepsy syndrome	5.7e-05	0.000145	CcSEcCtD
Salbutamol—Skin disorder—Topiramate—epilepsy syndrome	5.69e-05	0.000145	CcSEcCtD
Salbutamol—Hyperhidrosis—Topiramate—epilepsy syndrome	5.66e-05	0.000145	CcSEcCtD
Salbutamol—Hypersensitivity—Pregabalin—epilepsy syndrome	5.6e-05	0.000143	CcSEcCtD
Salbutamol—Anorexia—Topiramate—epilepsy syndrome	5.59e-05	0.000143	CcSEcCtD
Salbutamol—Dizziness—Valproic Acid—epilepsy syndrome	5.56e-05	0.000142	CcSEcCtD
Salbutamol—Urticaria—Gabapentin—epilepsy syndrome	5.53e-05	0.000141	CcSEcCtD
Salbutamol—Body temperature increased—Gabapentin—epilepsy syndrome	5.51e-05	0.000141	CcSEcCtD
Salbutamol—Abdominal pain—Gabapentin—epilepsy syndrome	5.51e-05	0.000141	CcSEcCtD
Salbutamol—Hypotension—Topiramate—epilepsy syndrome	5.48e-05	0.00014	CcSEcCtD
Salbutamol—Asthenia—Pregabalin—epilepsy syndrome	5.45e-05	0.000139	CcSEcCtD
Salbutamol—Pruritus—Pregabalin—epilepsy syndrome	5.37e-05	0.000137	CcSEcCtD
Salbutamol—Vomiting—Valproic Acid—epilepsy syndrome	5.34e-05	0.000136	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	5.34e-05	0.000136	CcSEcCtD
Salbutamol—Insomnia—Topiramate—epilepsy syndrome	5.3e-05	0.000135	CcSEcCtD
Salbutamol—Rash—Valproic Acid—epilepsy syndrome	5.3e-05	0.000135	CcSEcCtD
Salbutamol—Dermatitis—Valproic Acid—epilepsy syndrome	5.29e-05	0.000135	CcSEcCtD
Salbutamol—Headache—Valproic Acid—epilepsy syndrome	5.26e-05	0.000134	CcSEcCtD
Salbutamol—Paraesthesia—Topiramate—epilepsy syndrome	5.26e-05	0.000134	CcSEcCtD
Salbutamol—Dyspnoea—Topiramate—epilepsy syndrome	5.22e-05	0.000133	CcSEcCtD
Salbutamol—Somnolence—Topiramate—epilepsy syndrome	5.21e-05	0.000133	CcSEcCtD
Salbutamol—Diarrhoea—Pregabalin—epilepsy syndrome	5.2e-05	0.000133	CcSEcCtD
Salbutamol—Dyspepsia—Topiramate—epilepsy syndrome	5.16e-05	0.000132	CcSEcCtD
Salbutamol—Hypersensitivity—Gabapentin—epilepsy syndrome	5.13e-05	0.000131	CcSEcCtD
Salbutamol—Decreased appetite—Topiramate—epilepsy syndrome	5.09e-05	0.00013	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Topiramate—epilepsy syndrome	5.06e-05	0.000129	CcSEcCtD
Salbutamol—Fatigue—Topiramate—epilepsy syndrome	5.05e-05	0.000129	CcSEcCtD
Salbutamol—Dizziness—Pregabalin—epilepsy syndrome	5.02e-05	0.000128	CcSEcCtD
Salbutamol—Constipation—Topiramate—epilepsy syndrome	5.01e-05	0.000128	CcSEcCtD
Salbutamol—Pain—Topiramate—epilepsy syndrome	5.01e-05	0.000128	CcSEcCtD
Salbutamol—Asthenia—Gabapentin—epilepsy syndrome	5e-05	0.000128	CcSEcCtD
Salbutamol—Nausea—Valproic Acid—epilepsy syndrome	4.99e-05	0.000127	CcSEcCtD
Salbutamol—Pruritus—Gabapentin—epilepsy syndrome	4.93e-05	0.000126	CcSEcCtD
Salbutamol—Vomiting—Pregabalin—epilepsy syndrome	4.83e-05	0.000123	CcSEcCtD
Salbutamol—Feeling abnormal—Topiramate—epilepsy syndrome	4.83e-05	0.000123	CcSEcCtD
Salbutamol—Gastrointestinal pain—Topiramate—epilepsy syndrome	4.79e-05	0.000122	CcSEcCtD
Salbutamol—Rash—Pregabalin—epilepsy syndrome	4.79e-05	0.000122	CcSEcCtD
Salbutamol—Dermatitis—Pregabalin—epilepsy syndrome	4.78e-05	0.000122	CcSEcCtD
Salbutamol—Diarrhoea—Gabapentin—epilepsy syndrome	4.77e-05	0.000122	CcSEcCtD
Salbutamol—Headache—Pregabalin—epilepsy syndrome	4.76e-05	0.000122	CcSEcCtD
Salbutamol—Urticaria—Topiramate—epilepsy syndrome	4.65e-05	0.000119	CcSEcCtD
Salbutamol—Body temperature increased—Topiramate—epilepsy syndrome	4.63e-05	0.000118	CcSEcCtD
Salbutamol—Abdominal pain—Topiramate—epilepsy syndrome	4.63e-05	0.000118	CcSEcCtD
Salbutamol—Dizziness—Gabapentin—epilepsy syndrome	4.61e-05	0.000118	CcSEcCtD
Salbutamol—Nausea—Pregabalin—epilepsy syndrome	4.51e-05	0.000115	CcSEcCtD
Salbutamol—Vomiting—Gabapentin—epilepsy syndrome	4.43e-05	0.000113	CcSEcCtD
Salbutamol—Rash—Gabapentin—epilepsy syndrome	4.39e-05	0.000112	CcSEcCtD
Salbutamol—Dermatitis—Gabapentin—epilepsy syndrome	4.39e-05	0.000112	CcSEcCtD
Salbutamol—Headache—Gabapentin—epilepsy syndrome	4.36e-05	0.000111	CcSEcCtD
Salbutamol—Hypersensitivity—Topiramate—epilepsy syndrome	4.32e-05	0.00011	CcSEcCtD
Salbutamol—Asthenia—Topiramate—epilepsy syndrome	4.2e-05	0.000107	CcSEcCtD
Salbutamol—Pruritus—Topiramate—epilepsy syndrome	4.15e-05	0.000106	CcSEcCtD
Salbutamol—Nausea—Gabapentin—epilepsy syndrome	4.14e-05	0.000106	CcSEcCtD
Salbutamol—Diarrhoea—Topiramate—epilepsy syndrome	4.01e-05	0.000102	CcSEcCtD
Salbutamol—Dizziness—Topiramate—epilepsy syndrome	3.87e-05	9.9e-05	CcSEcCtD
Salbutamol—Vomiting—Topiramate—epilepsy syndrome	3.73e-05	9.52e-05	CcSEcCtD
Salbutamol—Rash—Topiramate—epilepsy syndrome	3.69e-05	9.44e-05	CcSEcCtD
Salbutamol—Dermatitis—Topiramate—epilepsy syndrome	3.69e-05	9.43e-05	CcSEcCtD
Salbutamol—Headache—Topiramate—epilepsy syndrome	3.67e-05	9.38e-05	CcSEcCtD
Salbutamol—Nausea—Topiramate—epilepsy syndrome	3.48e-05	8.89e-05	CcSEcCtD
Salbutamol—ADRB2—GPCR ligand binding—CCL2—epilepsy syndrome	3.43e-05	0.000388	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GNAO1—epilepsy syndrome	3.41e-05	0.000387	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—OPRD1—epilepsy syndrome	3.41e-05	0.000387	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AKT3—epilepsy syndrome	3.37e-05	0.000382	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CNR1—epilepsy syndrome	3.37e-05	0.000382	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CXCL12—epilepsy syndrome	3.36e-05	0.00038	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—BDKRB2—epilepsy syndrome	3.36e-05	0.00038	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PLCB1—epilepsy syndrome	3.36e-05	0.00038	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CHRM1—epilepsy syndrome	3.35e-05	0.000379	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GRM1—epilepsy syndrome	3.35e-05	0.000379	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PDYN—epilepsy syndrome	3.35e-05	0.000379	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCR7—epilepsy syndrome	3.35e-05	0.000379	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CNR1—epilepsy syndrome	3.29e-05	0.000373	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HTR7—epilepsy syndrome	3.29e-05	0.000372	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PLCB1—epilepsy syndrome	3.28e-05	0.000372	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PDYN—epilepsy syndrome	3.27e-05	0.000371	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CHRM1—epilepsy syndrome	3.27e-05	0.000371	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GRM1—epilepsy syndrome	3.27e-05	0.000371	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCR7—epilepsy syndrome	3.27e-05	0.000371	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HTR7—epilepsy syndrome	3.21e-05	0.000364	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HBEGF—epilepsy syndrome	3.19e-05	0.000361	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CDC42—epilepsy syndrome	3.15e-05	0.000356	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GFAP—epilepsy syndrome	3.15e-05	0.000356	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GAL—epilepsy syndrome	3.15e-05	0.000356	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AKT3—epilepsy syndrome	3.13e-05	0.000355	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HBEGF—epilepsy syndrome	3.12e-05	0.000354	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CASP2—epilepsy syndrome	3.11e-05	0.000352	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CHRM3—epilepsy syndrome	3.11e-05	0.000352	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GRM5—epilepsy syndrome	3.11e-05	0.000352	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CDC42—epilepsy syndrome	3.08e-05	0.000349	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GAL—epilepsy syndrome	3.08e-05	0.000349	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GFAP—epilepsy syndrome	3.08e-05	0.000349	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AKT3—epilepsy syndrome	3.06e-05	0.000347	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AVP—epilepsy syndrome	3.05e-05	0.000345	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GRM5—epilepsy syndrome	3.04e-05	0.000345	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CASP2—epilepsy syndrome	3.04e-05	0.000345	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CHRM3—epilepsy syndrome	3.04e-05	0.000345	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CX3CR1—epilepsy syndrome	2.98e-05	0.000338	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AVP—epilepsy syndrome	2.98e-05	0.000338	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CX3CL1—epilepsy syndrome	2.92e-05	0.000331	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CHRM2—epilepsy syndrome	2.92e-05	0.000331	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—BDKRB1—epilepsy syndrome	2.92e-05	0.000331	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CX3CR1—epilepsy syndrome	2.92e-05	0.000331	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PDXK—epilepsy syndrome	2.87e-05	0.000325	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ADK—epilepsy syndrome	2.87e-05	0.000325	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CERS1—epilepsy syndrome	2.87e-05	0.000325	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—L2HGDH—epilepsy syndrome	2.87e-05	0.000325	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GLUD1—epilepsy syndrome	2.87e-05	0.000325	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—FAR1—epilepsy syndrome	2.87e-05	0.000325	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CHRM2—epilepsy syndrome	2.86e-05	0.000324	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—BDKRB1—epilepsy syndrome	2.86e-05	0.000324	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CX3CL1—epilepsy syndrome	2.86e-05	0.000324	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CDC42—epilepsy syndrome	2.86e-05	0.000324	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GABBR1—epilepsy syndrome	2.84e-05	0.000322	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CDC42—epilepsy syndrome	2.79e-05	0.000317	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GABBR1—epilepsy syndrome	2.78e-05	0.000315	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AVP—epilepsy syndrome	2.77e-05	0.000313	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HRH3—epilepsy syndrome	2.73e-05	0.000309	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AVP—epilepsy syndrome	2.71e-05	0.000307	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—OPRM1—epilepsy syndrome	2.69e-05	0.000304	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HRH3—epilepsy syndrome	2.67e-05	0.000302	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—OPRM1—epilepsy syndrome	2.63e-05	0.000298	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PNPO—epilepsy syndrome	2.62e-05	0.000297	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NHLRC1—epilepsy syndrome	2.62e-05	0.000297	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—EPM2A—epilepsy syndrome	2.62e-05	0.000297	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GAMT—epilepsy syndrome	2.62e-05	0.000297	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CCR5—epilepsy syndrome	2.59e-05	0.000293	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCR3—epilepsy syndrome	2.54e-05	0.000287	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—HTR2A—epilepsy syndrome	2.53e-05	0.000287	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CCR5—epilepsy syndrome	2.53e-05	0.000287	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCR3—epilepsy syndrome	2.48e-05	0.000281	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—HTR2A—epilepsy syndrome	2.48e-05	0.000281	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NPY—epilepsy syndrome	2.47e-05	0.00028	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ATP2A2—epilepsy syndrome	2.47e-05	0.00028	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CA4—epilepsy syndrome	2.44e-05	0.000276	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—QDPR—epilepsy syndrome	2.44e-05	0.000276	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—POMC—epilepsy syndrome	2.43e-05	0.000276	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NPY—epilepsy syndrome	2.42e-05	0.000274	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ATP2A2—epilepsy syndrome	2.42e-05	0.000274	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AGT—epilepsy syndrome	2.4e-05	0.000272	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HSPB1—epilepsy syndrome	2.38e-05	0.00027	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCL3—epilepsy syndrome	2.38e-05	0.00027	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CRH—epilepsy syndrome	2.38e-05	0.00027	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—OXT—epilepsy syndrome	2.38e-05	0.00027	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CXCL2—epilepsy syndrome	2.38e-05	0.00027	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AGT—epilepsy syndrome	2.35e-05	0.000267	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CCR5—epilepsy syndrome	2.35e-05	0.000266	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HSPB1—epilepsy syndrome	2.33e-05	0.000264	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CRH—epilepsy syndrome	2.33e-05	0.000264	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CXCL2—epilepsy syndrome	2.33e-05	0.000264	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCL3—epilepsy syndrome	2.33e-05	0.000264	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—OXT—epilepsy syndrome	2.33e-05	0.000264	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HTR2A—epilepsy syndrome	2.3e-05	0.000261	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CCR5—epilepsy syndrome	2.3e-05	0.000261	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—COX3—epilepsy syndrome	2.29e-05	0.00026	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HTR2A—epilepsy syndrome	2.25e-05	0.000255	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PRKCB—epilepsy syndrome	2.22e-05	0.000252	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TSC1—epilepsy syndrome	2.22e-05	0.000251	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PTK2B—epilepsy syndrome	2.22e-05	0.000251	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AGT—epilepsy syndrome	2.18e-05	0.000247	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CACNA2D2—epilepsy syndrome	2.17e-05	0.000246	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—KCNB1—epilepsy syndrome	2.17e-05	0.000246	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PFKL—epilepsy syndrome	2.17e-05	0.000246	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLCO1A2—epilepsy syndrome	2.17e-05	0.000246	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC6A8—epilepsy syndrome	2.17e-05	0.000246	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PRKCB—epilepsy syndrome	2.17e-05	0.000246	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PTK2B—epilepsy syndrome	2.17e-05	0.000246	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TSC1—epilepsy syndrome	2.17e-05	0.000246	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NTRK2—epilepsy syndrome	2.16e-05	0.000244	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SST—epilepsy syndrome	2.16e-05	0.000244	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCR2—epilepsy syndrome	2.16e-05	0.000244	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—DUSP6—epilepsy syndrome	2.14e-05	0.000242	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AGT—epilepsy syndrome	2.14e-05	0.000242	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADRA2A—epilepsy syndrome	2.11e-05	0.000239	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SST—epilepsy syndrome	2.11e-05	0.000239	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NTRK2—epilepsy syndrome	2.11e-05	0.000239	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCR2—epilepsy syndrome	2.11e-05	0.000239	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PLAT—epilepsy syndrome	2.1e-05	0.000238	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—DUSP6—epilepsy syndrome	2.09e-05	0.000237	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ADRA2A—epilepsy syndrome	2.06e-05	0.000234	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PLAT—epilepsy syndrome	2.06e-05	0.000233	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—BDKRB2—epilepsy syndrome	2.03e-05	0.00023	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CXCL12—epilepsy syndrome	2.03e-05	0.00023	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—POMC—epilepsy syndrome	2.02e-05	0.000229	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PRKCB—epilepsy syndrome	2.02e-05	0.000229	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL6ST—epilepsy syndrome	2.01e-05	0.000228	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—JUNB—epilepsy syndrome	1.99e-05	0.000225	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CNR1—epilepsy syndrome	1.99e-05	0.000225	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NEU1—epilepsy syndrome	1.99e-05	0.000225	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—UPB1—epilepsy syndrome	1.99e-05	0.000225	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ATIC—epilepsy syndrome	1.99e-05	0.000225	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CXCL12—epilepsy syndrome	1.98e-05	0.000225	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—BDKRB2—epilepsy syndrome	1.98e-05	0.000225	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PLCB1—epilepsy syndrome	1.98e-05	0.000225	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—POMC—epilepsy syndrome	1.98e-05	0.000224	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PRKCB—epilepsy syndrome	1.97e-05	0.000224	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL6ST—epilepsy syndrome	1.97e-05	0.000223	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—JUNB—epilepsy syndrome	1.95e-05	0.000221	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CNR1—epilepsy syndrome	1.95e-05	0.000221	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HTR7—epilepsy syndrome	1.94e-05	0.00022	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PLCB1—epilepsy syndrome	1.94e-05	0.00022	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HSD17B4—epilepsy syndrome	1.91e-05	0.000217	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HTR7—epilepsy syndrome	1.9e-05	0.000215	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HBEGF—epilepsy syndrome	1.88e-05	0.000214	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AKT3—epilepsy syndrome	1.85e-05	0.00021	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GBE1—epilepsy syndrome	1.85e-05	0.000209	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PPP1R3C—epilepsy syndrome	1.85e-05	0.000209	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HBEGF—epilepsy syndrome	1.84e-05	0.000209	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—POMC—epilepsy syndrome	1.84e-05	0.000208	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AKT3—epilepsy syndrome	1.81e-05	0.000205	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADAM10—epilepsy syndrome	1.81e-05	0.000205	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CCL2—epilepsy syndrome	1.8e-05	0.000204	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—POMC—epilepsy syndrome	1.8e-05	0.000204	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ADAM10—epilepsy syndrome	1.77e-05	0.0002	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CCL2—epilepsy syndrome	1.76e-05	0.000199	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ASAH1—epilepsy syndrome	1.74e-05	0.000197	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—S100B—epilepsy syndrome	1.71e-05	0.000194	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SOCS3—epilepsy syndrome	1.69e-05	0.000192	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—STXBP1—epilepsy syndrome	1.69e-05	0.000192	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CDC42—epilepsy syndrome	1.69e-05	0.000191	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—S100B—epilepsy syndrome	1.67e-05	0.000189	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SOCS3—epilepsy syndrome	1.66e-05	0.000188	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CDC42—epilepsy syndrome	1.65e-05	0.000187	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NT5E—epilepsy syndrome	1.65e-05	0.000187	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALAD—epilepsy syndrome	1.65e-05	0.000187	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AVP—epilepsy syndrome	1.63e-05	0.000185	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AVP—epilepsy syndrome	1.6e-05	0.000181	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CACNA1A—epilepsy syndrome	1.57e-05	0.000178	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALDH7A1—epilepsy syndrome	1.57e-05	0.000178	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HES1—epilepsy syndrome	1.55e-05	0.000175	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ST3GAL3—epilepsy syndrome	1.54e-05	0.000174	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HES1—epilepsy syndrome	1.51e-05	0.000171	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ADSL—epilepsy syndrome	1.51e-05	0.000171	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FYN—epilepsy syndrome	1.5e-05	0.00017	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—H2AFX—epilepsy syndrome	1.5e-05	0.00017	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MEF2C—epilepsy syndrome	1.49e-05	0.000169	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GLUL—epilepsy syndrome	1.48e-05	0.000167	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FYN—epilepsy syndrome	1.47e-05	0.000167	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—H2AFX—epilepsy syndrome	1.46e-05	0.000166	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MEF2C—epilepsy syndrome	1.46e-05	0.000166	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	1.45e-05	0.000164	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—YWHAZ—epilepsy syndrome	1.44e-05	0.000164	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NGF—epilepsy syndrome	1.43e-05	0.000162	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—YWHAZ—epilepsy syndrome	1.41e-05	0.00016	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NGF—epilepsy syndrome	1.4e-05	0.000158	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCR5—epilepsy syndrome	1.39e-05	0.000157	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HTR2A—epilepsy syndrome	1.36e-05	0.000154	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCR5—epilepsy syndrome	1.36e-05	0.000154	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	1.36e-05	0.000154	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HTR2A—epilepsy syndrome	1.33e-05	0.000151	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AQP1—epilepsy syndrome	1.32e-05	0.000149	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TSC2—epilepsy syndrome	1.29e-05	0.000146	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AGT—epilepsy syndrome	1.29e-05	0.000146	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APOE—epilepsy syndrome	1.26e-05	0.000143	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TSC2—epilepsy syndrome	1.26e-05	0.000143	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AGT—epilepsy syndrome	1.26e-05	0.000143	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KDR—epilepsy syndrome	1.24e-05	0.00014	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APOE—epilepsy syndrome	1.24e-05	0.00014	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KDR—epilepsy syndrome	1.21e-05	0.000137	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PRKCB—epilepsy syndrome	1.19e-05	0.000135	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	1.19e-05	0.000135	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	1.19e-05	0.000135	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL6ST—epilepsy syndrome	1.19e-05	0.000135	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PRKCB—epilepsy syndrome	1.17e-05	0.000132	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL6ST—epilepsy syndrome	1.16e-05	0.000132	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—POMC—epilepsy syndrome	1.09e-05	0.000123	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCL2—epilepsy syndrome	1.06e-05	0.00012	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—POMC—epilepsy syndrome	1.06e-05	0.00012	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCL2—epilepsy syndrome	1.04e-05	0.000118	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	9.71e-06	0.00011	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FGF2—epilepsy syndrome	9.6e-06	0.000109	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	9.47e-06	0.000107	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	9.41e-06	0.000107	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FGF2—epilepsy syndrome	9.39e-06	0.000106	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RELA—epilepsy syndrome	8.91e-06	0.000101	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MTOR—epilepsy syndrome	8.74e-06	9.9e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RELA—epilepsy syndrome	8.72e-06	9.88e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MTOR—epilepsy syndrome	8.55e-06	9.69e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	8.49e-06	9.62e-05	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AKT1—epilepsy syndrome	8.11e-06	9.19e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	8.08e-06	9.16e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—BCHE—epilepsy syndrome	8.05e-06	9.12e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CASP3—epilepsy syndrome	8.04e-06	9.11e-05	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AKT1—epilepsy syndrome	7.94e-06	8.99e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CASP3—epilepsy syndrome	7.86e-06	8.91e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—JUN—epilepsy syndrome	7.81e-06	8.85e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	7.68e-06	8.7e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—JUN—epilepsy syndrome	7.64e-06	8.66e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MMP9—epilepsy syndrome	7.6e-06	8.61e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	7.59e-06	8.6e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TH—epilepsy syndrome	7.57e-06	8.57e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MMP9—epilepsy syndrome	7.43e-06	8.42e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AKT1—epilepsy syndrome	7.37e-06	8.35e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AKT1—epilepsy syndrome	7.21e-06	8.17e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SRC—epilepsy syndrome	7e-06	7.94e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SRC—epilepsy syndrome	6.85e-06	7.76e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—VEGFA—epilepsy syndrome	6.82e-06	7.73e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—VEGFA—epilepsy syndrome	6.67e-06	7.56e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	6.32e-06	7.16e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CAT—epilepsy syndrome	6.23e-06	7.06e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	6.06e-06	6.87e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GPX1—epilepsy syndrome	5.64e-06	6.38e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AGT—epilepsy syndrome	4.94e-06	5.6e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—APOE—epilepsy syndrome	4.84e-06	5.49e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AKT1—epilepsy syndrome	4.35e-06	4.93e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AKT1—epilepsy syndrome	4.26e-06	4.82e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—POMC—epilepsy syndrome	4.16e-06	4.71e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALB—epilepsy syndrome	3.79e-06	4.3e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	3.32e-06	3.76e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AKT1—epilepsy syndrome	1.67e-06	1.89e-05	CbGpPWpGaD
